XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
  Parkinson's
  Dementia
   Alzheimer's
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Alzheimer's Channel
subscribe to Alzheimer's newsletter

Latest Research : Aging : Dementia : Alzheimer's

   DISCUSS   |   EMAIL   |   PRINT
Imaging With Radiotracer FDG in Patients With Mild Cognitive Disorder Has Significantly Higher Accuracy
Oct 6, 2005, 23:19, Reviewed by: Dr.

"the assessment of cerebral glucose metabolism actually reflects ongoing pathological changes associated with Alzheimer's disease on a molecular level and that the molecular imaging method PET is capable of depicting subtle changes in the brain of MCI patients before a diagnosis of Alzheimer's based on neuropsychological evaluation is possible"

 
Positron emission tomography (PET) imaging�with the radiotracer fluorodeoxyglucose (FDG)�is a promising tool in detecting Alzheimer's disease in patients who have mild cognitive impairment (MCI), according to a study reported in the October issue of the Society of Nuclear Medicine's Journal of Nuclear Medicine.

"PET imaging with FDG represents one of the most promising tools for diagnosis of Alzheimer's," said Alexander Drzezga, M.D., who is the senior physician with the department of nuclear medicine at the Technical University of Munich in Germany. In fact, using PET imaging with FDG "may be the best indicator for determining which MCI patients are most at risk of developing Alzheimer's," added the lead author of "Prediction of Individual Clinical Outcome in Mild Cognitive Impairment (MCI) by Means of Genetic Assessment and 18F-FDG PET."

Mild cognitive impairment (MCI) is a term used to describe a subtle but measurable deterioration of cognitive capabilities, such as memory function. Individuals with MCI are able to function reasonably well in everyday activities, such as managing finances and purchasing items at stores without assistance, but may have difficulty remembering details of conversations, events and upcoming appointments.

Patients with MCI do not yet exhibit the criteria for the diagnosis of dementia, but the disorder is seen as a precursor to Alzheimer's disease, which takes years to develop in a person, said Drzezga. Many patients with MCI develop a progressive decline in their thinking abilities over time, and Alzheimer's disease is usually the underlying cause. Alzheimer's is the most common form of dementia among older people; it is a progressive, irreversible brain disorder with no known cause or cure. More than 4.5 million Americans suffer from Alzheimer's and its symptoms of memory loss, confusion, impaired judgment, personality changes, disorientation and loss of language skills.

"A high percentage of MCI patients will develop Alzheimer's disease within a year; however, some of these patients will never develop dementia and may even improve with time," said Drzezga. Most MCI patients who showed abnormalities typical of Alzheimer's in their original PET scan developed dementia within 16 months, according to findings from the 30-patient study. Most patients who did not show abnormalities in their original PET scan remained stable, he added.

Patients with Alzheimer's show characteristic changes of the cerebral glucose metabolic pattern, with a decrease in affected brain regions, said Drzezga. PET imaging with FDG allows the analysis of regional cerebral glucose metabolism. The study showed that "the assessment of cerebral glucose metabolism actually reflects ongoing pathological changes associated with Alzheimer's disease on a molecular level and that the molecular imaging method PET is capable of depicting subtle changes in the brain of MCI patients before a diagnosis of Alzheimer's based on neuropsychological evaluation is possible," said Drzezga.

The study revealed that PET with FDG has a significantly higher accuracy for detection of Alzheimer's than the genetic screening for the APOEe4-risk factor. In addition, using both PET with FDG and the APOEe4-genotype as genetic markers "allowed the definition of subgroups of patients with very high risk and with very low risk," he added. This finding could have implications for risk stratifying MCI patients in therapeutic trials, said Drzezga. "This study implies that PET�and in consequence nuclear medicine�should continue to be strongly involved in the challenging process of Alzheimer's research for early diagnosis as well as for the development and evaluation of new treatment options," he added.

Although there is currently no cure for Alzheimer's, new treatments are on the horizon as a result of accelerating insight into the biology of the disease. "It is of increasing importance to identify 'converters' at the earliest possible stage of disease to develop and evaluate new and upcoming treatment options for Alzheimer's," added Drzezga, an SNM member.

PET is a safe, effective and painless biological imaging exam that "photographs" or detects the presence and extent of neurological conditions. PET uses very small amounts of radioactive materials that are targeted to specific organs, bones or tissues. Radiotracers (such as FDG) are injected and then detected by a special type of camera that works with computers to provide precise pictures of the area of the body being imaged and molecular images of the body's biological functions. "The combination of molecular imaging with genotype assessment represents the unique opportunity to interpret imaging findings in the context of background information," explained Drzezga. "As we increase our understanding of the human genome, individualized therapy and individualized diagnosis will become increasingly important," he added. "The current study underlines that a genetic disposition does not necessarily represent a determined prognosis, thus, the need for measures that allow the definition of the actual onset of a disease process is apparent. Molecular imaging could play an important role in this context," he stated.
 

- Journal of Nuclear Medicine
 

www.snm.org

 
Subscribe to Alzheimer's Newsletter
E-mail Address:

 

The Society of Nuclear Medicine is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular imaging/nuclear medicine. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

Related Alzheimer's News

Hope remains for Alzheimer's sufferers
CATIE Study: Antipsychotics in Alzheimer's No Better Than Placebo
Mediterranean diet associated with a lower risk for Alzheimer�s disease
Omega-3 fatty acid supplements may slow cognitive decline
Microscopic brain damage detected in early Alzheimer's disease
Novel technique can identify early cellular damage in Alzheimer's disease
Cathepsin B - Part of protective mechanism against Alzheimer's
Boosting ubiquitin C-terminal hydrolase L1 (Uch-L1) restores lost memory
New research points toward mechanism of age-onset toxicity of Alzheimer's protein
Structure of calbindin-D28K Protein Involved in Preventing Alzheimer�s, Huntington�s Diseases Characterised


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us